A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)
NCT ID: NCT01104519
Last Updated: 2015-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
12 participants
INTERVENTIONAL
2008-03-31
2008-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)
NCT01071291
Study to Test GSK256073 in Patients With Dyslipidemia
NCT00903617
Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Acute Coronary Syndrome
NCT00855257
Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy
NCT00108485
Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia
NCT01216956
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Niaspan - Placebo
Niaspan
Oral doses of 2000 mg of Niaspan once daily for 7 days.
Comparator: Placebo
Oral doses of placebo once daily for 7 days.
2
Placebo - Niaspan
Niaspan
Oral doses of 2000 mg of Niaspan once daily for 7 days.
Comparator: Placebo
Oral doses of placebo once daily for 7 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Niaspan
Oral doses of 2000 mg of Niaspan once daily for 7 days.
Comparator: Placebo
Oral doses of placebo once daily for 7 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is in good health (other than history of high cholesterol)
* Subject is a non-smoker
Exclusion Criteria
* Subject has a history of cancer
* Subject is unable to refrain from or anticipates the use any prescription or non-prescription drugs
* Subjects consumes excessive amounts of alcohol or caffeine
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
093
Identifier Type: -
Identifier Source: secondary_id
2010_524
Identifier Type: -
Identifier Source: secondary_id
0000-093
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.